Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
|Articles|May 15, 2021
- Pharmaceutical Technology-05-15-2021
- Volume 2021 eBook
- Issue 2
Reducing Packaging Costs for Prefilled Syringes
Author(s)Beth Totin, Marcus Webb
Blow-fill-seal (BFS) technology presents an economical option for single-unit dose delivery of vaccines.
Advertisement
Blow-fill-seal (BFS) technology presents an economical option for single-unit dose delivery of vaccines. Currently used for over-the-counter products, prescription medicines, and more than 50 injectable products, the authors present the case for using BFS for prefilled syringes. Factors including drug formulation, material compatibility, extractables and leachables, sterilization, and regulatory approval must be considered.
About the authors
Beth Totin is chief commercial officer, and Marcus Webb is director of communications, both with ApiJect Systems, Corp.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2021
May 2021
Pages: 54–59
Citation
When referring to this article, please cite it as B. Totin and M. Webb, “Reducing Packaging Costs for Prefilled Syringes," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2021).
Articles in this issue
over 5 years ago
Sterile Filtration: Reducing Risk, Ensuring Safetyover 5 years ago
Filling Small Batchesover 5 years ago
Breaking the Cold Chain for Vaccinesover 5 years ago
Using ddPCR to Detect Mycoplasma Contaminationover 5 years ago
The Impact of COVID-19 on Biologics Regulationsover 5 years ago
Packaging Biologic Drugs for Clinical Trialsover 5 years ago
Tracking Technologies Guard Vaccine Cold Chainover 5 years ago
Eyeing Up Success in Fill/Finishover 5 years ago
Biologics Facilities Expand and Establish New Locations in 2021Advertisement
Related to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement